- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | ViroGates A/S: ViroGates announces its half-year report for H1 2026 | 66 | GlobeNewswire (Europe) | Company Announcement no. 9/2026 (August 20, 2026)
Revenue grew significantly compared to H1 2025, driven largely by U.S. partner building up stock for market roll-out
BIRKERØD, DENMARK - ViroGates A/S... ► Artikel lesen | |
| 03.08. | ViroGates A/S: ViroGates announces changes to its commercial organization | 152 | GlobeNewswire (Europe) | Company Announcement no. 6/2026 (August 03, 2026)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates"), a medical technology company developing blood tests for measuring chronic inflammation at health clinics... ► Artikel lesen | |
| VIROGATES Aktie jetzt für 0€ handeln | |||||
| 07.05. | Virogates A/S Q1 Loss Drops | - | RTTNews | ||
| 07.05. | ViroGates A/S: ViroGates announces its Interim Report for Q1-2026 | 216 | GlobeNewswire (Europe) | Company Announcement no. 5/2026 (May 07, 2026 at 13:12:00 CEST)
Revenue increased 8% Y-o-Y in Q1 to DKK 1.3 million, and net loss decreased by 6% to DKK 2.6 million
BIRKERØD, DENMARK - ViroGates A/S... ► Artikel lesen | |
| 23.04. | ViroGates A/S: Resolutions from the Annual General Meeting of ViroGates A/S | 180 | GlobeNewswire (Europe) | Company Announcement no. 4/2026 (April 23, 2026 at 20:15:00 CEST)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring... ► Artikel lesen | |
| 08.04. | ViroGates A/S: ViroGates submits its De Novo application to the U.S. FDA for suPARnostic TurbiLatex | 378 | GlobeNewswire (Europe) | Company Announcement no. 3/2026 (April 08, 2026 at 22:37:00 CEST)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 26.03. | ViroGates A/S: ViroGates announces its Annual Report 2025: Revenue growth and improved operating result as strategic transition towards preventive health and longevity continues | 772 | GlobeNewswire (Europe) | Company Announcement no. 1/2026 (March 26, 2026 at 15:10:00 CET)
Inside information
BIRKERØD, DENMARK ViroGates A/S ("ViroGates" or "Company"), a medical technology company developing blood tests for... ► Artikel lesen | |
| 12.12.25 | ViroGates A/S: ViroGates announces financial guidance for 2026 | 248 | GlobeNewswire (Europe) | Company Announcement no. 22/2025 (December 12, 2025)
BIRKERØD, DENMARK-ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 28.11.25 | ViroGates A/S: ViroGates' capital raise of DKK 19.3 million and issue of 1,547,412 shares have been registered and settled | 429 | GlobeNewswire (Europe) | Company Announcement no. 21/2025 (November 28, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company") announces that the capital raise of approximately DKK 19.3 million and the issue... ► Artikel lesen | |
| 26.11.25 | ViroGates A/S - increase | 287 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North Growth Market Denmark as of 28 November 2025. New shares are issued due to a directed issue of new shares.
Name:
ViroGates
ISIN:
DK0061030574
Short... ► Artikel lesen | |
| 12.11.25 | ViroGates A/S - Observation status | 263 | GlobeNewswire | Nasdaq Copenhagen has today removed observation status for:
ISIN NAME
DK0061030574 VIROGATES
The company's observation status has been removed... ► Artikel lesen | |
| 12.11.25 | ViroGates A/S: suPAR Remedy, LLC announces the outcome of the Public Tender Offer to the shareholders of ViroGates | 285 | GlobeNewswire (Europe) | Company Announcement no. 17/2025 (November 12, 2025)
BIRKERØD, DENMARK - Today, suPAR Remedy, LLC (the "Offeror") announces the outcome of the public tender offer published on 8 October 2025 and on... ► Artikel lesen | |
| 06.11.25 | ViroGates A/S: ViroGates announces its Interim Report for Q1-Q3 2025 | 258 | GlobeNewswire (Europe) | Company Announcement no. 16/2025 (November 06, 2025)
Revenue rose 49% Y-o-Y in Q3, and total revenue for the first nine months is now slightly above the same period in 2024
BIRKERØD, DENMARK - ViroGates... ► Artikel lesen | |
| 08.10.25 | ViroGates A/S - Observation status | 309 | GlobeNewswire | Nasdaq Copenhagen has given the company below observation status:
ISIN DK0061030574 Symbol VIRO
ViroGates A/S has been given observation status, as the company has announced that suPAR... ► Artikel lesen | |
| 08.10.25 | ViroGates A/S: suPAR Remedy, LLC announces public tender offer to the shareholders of ViroGates A/S at a 40% premium | 363 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Company... ► Artikel lesen | |
| 21.08.25 | ViroGates A/S: ViroGates announces its Half-Year Report for H1 2025 | 259 | GlobeNewswire (Europe) | Company Announcement no. 10/2025 (August 21, 2025)
Revenue ending 18% below H1 2024, operating loss reduced by 26%, and proof of concept achieved for suPARnostic® POC+ in longevity
BIRKERØD, DENMARK... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS | 39,640 | -0,05 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,47 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 364,38 | -0,05 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| APOGEE THERAPEUTICS | 134,78 | +0,02 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| NURIX THERAPEUTICS | 27,050 | 0,00 % | Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,760 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,360 | +0,04 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,430 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| COGENT BIOSCIENCES | 35,310 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 59,02 | +0,17 % | William Blair startet Coverage für Enliven Therapeutics mit "Outperform" | ||
| RECURSION PHARMACEUTICALS | 3,335 | -0,15 % | Recursion, Novavax and Crispr Stocks Trending in Pre-Market-Here's Why | ||
| STRUCTURE THERAPEUTICS | 50,52 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| JADE BIOSCIENCES | 21,230 | 0,00 % | Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors | SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the "Company" or "Jade") (Nasdaq: JBIO), a clinical-stage biotechnology company focused on... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,520 | 0,00 % | H.C. Wainwright hebt Kursziel für Tango Therapeutics auf 68 US-Dollar an | ||
| BEAM THERAPEUTICS | 28,370 | -0,07 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen |
VIROGATES A/S gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIROGATES A/S finden Sie auf Wallstreet Online.